Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com      SPECIAL REPORT #33     Will AstraZeneca-Oxford vaccine get U.K. approval before EU?     AstraZeneca and Oxford University COVID-19 vaccine AZD1222 is making headlines since Monday 23 November when its efficacy data were first disclosed. The results came in as a surprise […]

Looking for additional & highly qualified human ressource for your business development on focus mission  Looking for partners for licensing-out or for grant application Looking for international customers for your products or services Meeting us at :  Biotechgate Digital Partnering NOV 23-26 Infectious Diseases Virtual Partnering Dec 2-4 or send me an email to plan […]

    Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com                                          SPECIAL REPORT #32                                     Progress in COVID-19 Treatments   The month of November 2020 will undoubtedly remain a major milestone in the race engaged by the biopharmaceutical companies to find, develop and register treatments targeting the SARS-CoV-2 virus.   On November 9, […]

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com          SPECIAL REPORT #31   BioNTech et Pfizer have submitted an emergency use authorisation for BNT162b their Covid-19 vaccine candidate     On Friday November 20, in an exclusive TIME 100 Talks, Pfizer CEO Albert Bourla announced that his company has submitted […]

    Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com            Sécurité et tolérance d'un vaccin COVID-19       Faisant suite à mon dernier « billet » relatant les résultats positifs du vaccin BNT162b découvert par BioNtech et co-développé par Pfizer, vous avez été nombreux à me questionner sur un enjeu […]

    Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com         SPECIAL REPORT #30   BioNTech et Pfizer enregistrent un premier succès dans lutte contre la COVID-19   Le 2 novembre dernier je vous ai décrit l’état de préparation du plan logistique allemand pour expédier des dizaines de milliers de doses du […]

Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com              COVID Vaccines in Germany     In a TV interview with the editorial staff of the Wiesbadener Kurier, Professor Ugur Sahin, CEO of the Mainz-based biotech company BioNtech, explains at length the status of BNT162b, the SARS-CoV-2 vaccine he discovered […]